Oncology News | pharmaphorum

News

GSK bails on $4.2bn partnership with Merck on cancer drug

GlaxoSmithKline has ended its collaboration with Germany's Merck KGaA's cancer treatment bintrafusp alfa, after a trio of failed clinical trials.

News

Keytruda's liver cancer approval secured by new study

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients.

News

PROpel study backs Lynparza combo in first-line prostate can...

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug's use broadened after a p

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer buys Abexxa, bolstering its immuno-oncology pipel...

Boehringer Ingelheim has agreed to buy US biotech Abexxa Biologics, its second acquisition in the cancer immunotherapy area in the space of a year.

News

FDA clears Seagen, Genmab's Tivdak ADC for cervical cancer

Antibody-drug conjugate (ADC) specialist Seagen has claimed its fourth product approval in the US, getting the nod from the FDA for Tivdak as a second-line monotherapy for recurrent or meta

News

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

There's no shortage of cancer immunotherapies trying to knock Merck & Co's Keytruda off the top of the tree in previously-untreated non-small cell lung cancer (NSCLC).

GSK bails on $4.2bn partnership with Merck on cancer drug

Keytruda's liver cancer approval secured by new study

PROpel study backs Lynparza combo in first-line prostate can...

Boehringer buys Abexxa, bolstering its immuno-oncology pipel...

FDA clears Seagen, Genmab's Tivdak ADC for cervical cancer

ESMO21: Libtayo extends survival in first-line NSCLC, challe...

Vanda ends 40-year hiatus for new motion sickness drugs

How to meet your physicians where they are online

News

Editor's Picks